Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.94SMS Pharmaceuticals demonstrates a mixed financial profile. The company shows strong solvency and profitability, indicating a solid foundation and efficient management of resources. Revenue and asset growth are also robust, suggesting expansion and effective use of assets. However, the company faces challenges in efficiency, particularly in inventory and receivables management. Earnings per share and net income growth have been volatile, reflecting potential instability in earnings. Liquidity is adequate, but there is room to improve short-term financial obligations. Overall, SMS Pharmaceuticals exhibits financial strengths but needs to address certain operational inefficiencies and earnings inconsistencies to enhance its long-term financial health.
Health Score : 5.94SMS Pharmaceuticals demonstrates a mixed financial profile. The company shows strong solvency and profitability, indicating a solid foundation and efficient management of resources. Revenue and asset growth are also robust, suggesting expansion and effective use of assets. However, the company faces challenges in efficiency, particularly in inventory and receivables management. Earnings per share and net income growth have been volatile, reflecting potential instability in earnings. Liquidity is adequate, but there is room to improve short-term financial obligations. Overall, SMS Pharmaceuticals exhibits financial strengths but needs to address certain operational inefficiencies and earnings inconsistencies to enhance its long-term financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
39.39
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
33.82
P/B RATIO
4.39
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
3.84
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
19.62
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹368.25 as on Sep 1, 2026.
Growth Score : 6.00The growth ratios show positive trends in revenue and asset growth, but inconsistencies in earnings per share and net income growth may indicate earnings instability. While revenue and asset growth demonstrate the company's ability to expand, the negative growth in earnings per share and net income requires attention to ensure sustainable profitability. Improving earnings stability is crucial for long-term growth.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -7.64 | 0.38 | 35.82 | 10.44 | 13.28 |
| Operating Profit Growth Rate | -4.96 | -52.17 | 112.73 | 18.8 | 23.02 |
| Earnings Per Share (EPS) Growth | -0.41 | -111.29 | 808.43 | 32.65 | 39.62 |
| Asset Growth Rate | 5.91 | 2.33 | 17.5 | 11.51 | 18.13 |
| Net Income Growth Rate | -1.59 | -111.29 | 814.29 | 38 | 47.83 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 6 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 13 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 17 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 20 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 21 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 22 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤7th Feb 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Concall Report⬤11th Nov 25
Q2 & H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
SMS Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. It caters to both domestic and international markets, offering a diverse portfolio across therapeutic segments like anti-ulcerants, anti-fungals, and anti-retrovirals, establishing itself as a key supplier in the global API space.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. SMS Pharmaceuticals Ltd's P/E ratio (TTM) is 39.39, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. SMS Pharmaceuticals Ltd's P/B ratio is 4.39, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. SMS Pharmaceuticals Ltd's P/S ratio is 3.84, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. SMS Pharmaceuticals Ltd's PEG ratio is 1.50.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. SMS Pharmaceuticals Ltd's EV/EBITDA ratio is 19.62.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. SMS Pharmaceuticals Ltd's ROE is 12.99%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. SMS Pharmaceuticals Ltd's ROA is 12.56%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. SMS Pharmaceuticals Ltd's ROCE is 13%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. SMS Pharmaceuticals Ltd's operating margin is 19.28%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. SMS Pharmaceuticals Ltd's net margin is 11.50%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. SMS Pharmaceuticals Ltd's current ratio is 1.68.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. SMS Pharmaceuticals Ltd's debt-to-equity ratio is 0.22.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. SMS Pharmaceuticals Ltd's interest coverage ratio is 6.09.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. SMS Pharmaceuticals Ltd's DPS is ₹0.44.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. SMS Pharmaceuticals Ltd's EPS is 39.62.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹368.25. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1987
Headquarters: Hyderabad, Telangana
Core Offerings: Active Pharmaceutical Ingredients (APIs), Drug Intermediates, Contract Manufacturing and Research Services (CRAMS)
Stock Listing: NSE (SMSPHARMA), BSE (532815)
Promoter: Potluri Family / SMS Group
SMS Pharmaceuticals Ltd. was incorporated in 1987. Since its inception, the company has steadily expanded its manufacturing capabilities and product portfolio, evolving into a key player in the API manufacturing sector. It has achieved significant milestones through continuous investment in R&D and securing regulatory approvals for its state-of-the-art facilities, solidifying its presence in both Indian and global pharmaceutical markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) & Intermediates | Approx. 95% | Operating Profit |
| Contract Manufacturing Services | Approx. 5% | Operating Profit |
Active Pharmaceutical Ingredients (APIs) & Intermediates: Manufactures a wide spectrum of APIs used in various therapeutic areas, including anti-ulcerants, anti-fungals, anti-retrovirals, and anti-diabetics. The company operates multiple manufacturing facilities approved by major global regulatory bodies like USFDA, EUGMP, and WHO-GMP.
Contract Manufacturing and Research Services (CRAMS): Provides tailored development and manufacturing services to pharmaceutical companies, leveraging its advanced R&D capabilities and robust manufacturing infrastructure to meet specific client requirements.
P.V. Raja Ram Prasad - Chairman & Managing Director. A founding promoter, Mr. Prasad brings extensive industry experience, guiding the company's strategic vision, operational excellence, and growth trajectory.
SMS Pharmaceuticals Inc. (USA)
SMS Lifesciences Private Limited
Bonus Shares: 1:4 bonus issue in February 2024.
The SMS Pharmaceuticals Ltd share price today is ₹368.25 on NSE (SMSPHARMA), as of 26 Sept 2026.
As of 25 Sept 2026, SMS Pharmaceuticals Ltd share price is ₹368.25, with previous close ₹368.25. Today's range is ₹368.25 to ₹368.25. The 52-week range is ₹293.15 to ₹494.45.
As of today, SMS Pharmaceuticals Ltd's market cap is ₹3,406.31 crore (Small Cap).
SMS Pharmaceuticals Ltd's current P/E ratio is 39.39, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 36.
SMS Pharmaceuticals Ltd's current P/B ratio is 4.39.
SMS Pharmaceuticals Ltd's current dividend yield is 0.12%. Last dividend of ₹0.50 per share was declared on 22-Sep-2023.
SMS Pharmaceuticals Ltd's EPS (TTM) is ₹39.62.
SMS Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. It caters to both domestic and international markets, offering a diverse portfolio across therapeutic segments like anti-ulcerants, anti-fungals, and anti-retrovirals, establishing itself as a key supplier in the global API space.
SMS Pharmaceuticals Ltd is promoted by Potluri Family / SMS Group, holding 68.07% as of 25 Sept 2026.
SMS Pharmaceuticals Ltd is listed on NSE (SMSPHARMA) and BSE (532815). Its next quarterly results are expected on August 2024 (Q1 FY25).
Interest Coverage Ratio
